GlassScriptPhysician profile
Sara M May
NPI 1073741815
$1,828.48
in general payments reported to CMS, 2019-2025
14 companies · $363 in 2025
The $363 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $49.71 · 2020: $31.84 · 2021: $118 · 2022: $204 · 2023: $1,013 · 2024: $48.74 · 2025: $363.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,287 · Education: $107 · Consulting Fee: $30.04.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,287.45 |
| Education | $107.26 |
| Consulting Fee | $30.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $418.82 | 2023-2024 | Xolair |
| Genzyme Corporation | $354.46 | 2021-2025 | |
| Horizon Therapeutics Plc | $269.23 | 2020-2023 | Actimmune |
| Csl Behring | $171.96 | 2019-2025 | Hizentra |
| Takeda Pharmaceuticals U.S.A., INC. | $144.93 | 2022-2023 | Cuvitru |
| Pharming Healthcare, INC. | $138.34 | 2020-2025 | |
| Sanofi US Services INC. | $124.83 | 2025 | |
| Sanofi-Aventis U.S. LLC | $91.99 | 2023 | |
| Adma Biomanufacturing LLC | $30.04 | 2025 | |
| Biocryst US Sales Co., LLC | $25.94 | 2021 | |
| Pfizer INC. | $15.27 | 2023 | |
| Fisher & Paykel Healthcare INC | $15.04 | 2025 | Fisher & Paykel Healthcare |
| Astrazeneca Pharmaceuticals LP | $14.95 | 2019 | |
| Medtronic, INC. | $12.68 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara May listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.